Is Sarepta Therapeutics (SRPT) the Best Mid Cap Biotech Stock to Buy?
We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...
Sarepta: Disclosure Of An Elevidys Patient's Death Creates Market Uncertainty
Sarepta Therapeutics shares dropped 20% after a patient's death raises Elevidys safety concerns. Read why I am downgrading ...
Teenager who received Elevidys, Sarepta’s Duchenne gene therapy, dies
Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was ...
BioPharma Dive11d
Duchenne patient dies after receiving Sarepta gene therapy
A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...
pharmaphorum10d
Sarepta slumps on Elevidys patient death
The tragic death of the 16-year-old boy came as a result of acute liver failure, which is a known side effect of Elevidys and ...
Neurology Advisor1d
Patient Dies Following Treatment With DMD Gene Therapy Elevidys
Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.
Managed Healthcare Executive2d
Death of Elevidys Patient Rattles Duchenne Community
The patient died of acute liver failure; the maker of the gene therapy noted that the patient also had a recent ...
Business Insider11d
Analysts remain optimistic about Elevidys after Sarepta reports patient death
Shares of Sarepta Therapeutics (SRPT) are under pressure on Tuesday after the company shared a safety update related to its Elevidys, the only approved gene therapy in patients with Duchenne ...
Fierce Pharma11d
Sarepta reports one death after patient received DMD gene therapy Elevidys
One patient with Duchenne muscular dystrophy (DMD) has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys, the biotech ...
Sarepta Therapeutics Stock Sinks After Company Says Patient Taking Its Drug Dies
Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure.
GEN - Genetic Engineering and Biotechnology News11d
DMD Patient Dies After Treatment with Sarepta Gene Therapy
The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...
BofA says Elevidys risk-reward favorable despite Sarepta report of patient death
After Sarepta (SRPT) reported the death of a Duchenne muscular dystrophy patient following treatment with Elevidys after suffering acute liver ...